European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
Usefulness of routine clinical follow-up after oral cavity cancer treatment: a single-center retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guibert Alexandre, Vergez Sébastien, Dupret-Bories Agnès, Vairel Benjamin, Sarini Jérôme, Rivière Louis-David, Modesto Anouchka, Piram Lucie, Morisseau Mathilde, Chabrillac Emilien
Аннотация
INTRODUCTION: Follow-up for Oral Cavity Squamous Cell Carcinoma (OCSCC) imposes a heavy financial burden on healthcare systems. The survival benefits of recommended clinical monitoring models remains unproven. This study aimed to determine whether the mode of detection for locoregional recurrences or head and neck second primary tumors (SPT) influences tumor stages and survival outcomes.
METHODS: This single-center retrospective study included 351 patients surgically treated for primary OCSCC between 2015 and 2022. The primary endpoint was the occurrence of a Head and Neck Event (HNE), defined as locoregional recurrence or head and neck SPT. Post-Event Survival (PES) was analyzed using a lead-time bias correction. We calculated the Number Needed to See (NNS) to detect one asymptomatic HNE, and the average cost of a routine follow-up visit.
RESULTS: HNEs occurred in 92 (26.2%) patients. They were detected during routine visits for 48 (52.7%) patients and interval visits for 43 (47.3%). Neither HNE tumor stage (p = 0.718) nor curative treatment intent (p = 0.405) was significantly associated with the type of detection visit. The median PES was 10.3 months, with no significant difference observed between routine and interval detections (p = 0.504). The average visit cost was €166. The NNS was 547 during the first two years (equivalent to €90,802), and 255 during the years two to five (equivalent to €42,330).
CONCLUSION: Routine clinical follow-up is not associated with improved PES or lower tumor stage in OCSCC patients. Recommended surveillance models demonstrate a low diagnostic yield. Follow-up should transition toward risk-stratified, tailored regimens emphasizing patient empowerment and sustainability.
METHODS: This single-center retrospective study included 351 patients surgically treated for primary OCSCC between 2015 and 2022. The primary endpoint was the occurrence of a Head and Neck Event (HNE), defined as locoregional recurrence or head and neck SPT. Post-Event Survival (PES) was analyzed using a lead-time bias correction. We calculated the Number Needed to See (NNS) to detect one asymptomatic HNE, and the average cost of a routine follow-up visit.
RESULTS: HNEs occurred in 92 (26.2%) patients. They were detected during routine visits for 48 (52.7%) patients and interval visits for 43 (47.3%). Neither HNE tumor stage (p = 0.718) nor curative treatment intent (p = 0.405) was significantly associated with the type of detection visit. The median PES was 10.3 months, with no significant difference observed between routine and interval detections (p = 0.504). The average visit cost was €166. The NNS was 547 during the first two years (equivalent to €90,802), and 255 during the years two to five (equivalent to €42,330).
CONCLUSION: Routine clinical follow-up is not associated with improved PES or lower tumor stage in OCSCC patients. Recommended surveillance models demonstrate a low diagnostic yield. Follow-up should transition toward risk-stratified, tailored regimens emphasizing patient empowerment and sustainability.